OBJECTIVES: After completing this course, learners will be able to: 1) understand the current therapeutic landscape for ALS, 2) explain key clinical trial design strategies in ALS, 3) describe the platform trial approach in ALS.

ACCREDITATION STATEMENT: The AANEM is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION: The AANEM designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. AANEM also designates this enduring material for a maximum of  0.5 CEU credits.


DISCLOSURE INFORMATION: The presenters had no relevant conflicts to disclose.

Content from this presentation is not to be used without express written permission of the AANEM and the presenters involved in the presentation.